Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.65Last Year’s EPS
0.61Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 4.78%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive trajectory for Teva Pharmaceuticals, highlighted by continued growth in its innovative brands and a strategic focus on biosimilar launches and cost savings to drive future growth. Despite challenges in the generic segment and uncertainties related to tariffs and specific product headwinds, Teva remains confident in achieving its financial targets through focused capital allocation and operational efficiencies.Company Guidance
In the Q1 2025 earnings call for Teva Pharmaceutical Industries Limited, leadership highlighted several key metrics that emphasize the company's growth trajectory and strategic focus. Revenue increased by 5% to $3.9 billion, marking the ninth consecutive quarter of growth. Adjusted EBITDA rose by 3%, while non-GAAP EPS reached $0.52, an 8% increase. The company's innovative brands, Austedo, Ajovy, and Uzedy, were strong contributors, with Austedo's sales growing 39% globally, Ajovy up 26%, and Uzedy sales doubling to $39 million. Additionally, Teva's generic business saw a 3% growth, and biosimilar launches are expected to further support revenue. The company is focused on achieving a 30% operating margin by 2027, with planned savings of $700 million from operational efficiencies, and aims for sustainable growth driven by its innovative portfolio and disciplined capital allocation.Ninth Consecutive Quarter of Growth
Teva Pharmaceutical Industries has achieved its ninth consecutive quarter of growth, with revenue up 5% to $3.9 billion.
Strong Performance of Innovative Brands
Innovative brands reached $589 million in sales, a 45% increase over last year. Austedo grew 39%, Ajovy increased by 26%, and Uzedy's sales doubled.
Positive Outlook and Biosimilar Launches
Teva plans to launch five new biosimilar products from 2025 to 2027, with potential for some to launch in 2025, further supporting growth.
Improved Financial Metrics
Non-GAAP EPS increased by 8% to $0.52, and the adjusted EBITDA grew by 3%. Gross margin improved by 140 basis points year-over-year to 52.8%.
Debt Reduction and Strong Cash Flow
Net debt reduced to $15 billion, with a net debt-to-EBITDA ratio just over three times. Free cash flow is strong, aligning with long-term goals.
Cost Savings and Margin Expansion Plan
Teva plans to achieve $700 million in net savings by 2027, improving operating margins to 30% by 2027.
---
TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $16.12 | $17.60 | +9.18% |
Jan 29, 2025 | $21.53 | $18.54 | -13.89% |
Nov 06, 2024 | $18.77 | $17.43 | -7.14% |
Jul 31, 2024 | $16.41 | $17.43 | +6.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Teva Pharmaceutical (TEVA) report earnings?
Teva Pharmaceutical (TEVA) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Teva Pharmaceutical (TEVA) earnings time?
Teva Pharmaceutical (TEVA) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TEVA EPS forecast?
TEVA EPS forecast for the fiscal quarter 2025 (Q2) is 0.65.
---
